NasdaqGS - Nasdaq Real Time Price USD
Innoviva, Inc. (INVA)
At close: November 22 at 4:00 PM EST
After hours: November 22 at 6:09 PM EST
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
352,745.00
310,463.00
331,339.00
391,866.00
336,794.00
Cost of Revenue
42,563.00
42,640.00
13,793.00
--
--
Gross Profit
310,182.00
267,823.00
317,546.00
391,866.00
336,794.00
Operating Expense
148,929.00
153,938.00
110,551.00
16,763.00
15,671.00
Operating Income
161,253.00
113,885.00
206,995.00
375,103.00
321,123.00
Net Non Operating Interest Income Expense
-5,253.00
-3,339.00
-9,420.00
-17,231.00
-16,807.00
Other Income Expense
-82,105.00
83,552.00
89,374.00
87,404.00
49,929.00
Pretax Income
73,895.00
194,098.00
286,949.00
445,276.00
354,245.00
Tax Provision
9,304.00
14,376.00
66,687.00
76,439.00
60,431.00
Net Income Common Stockholders
64,591.00
179,722.00
213,921.00
265,854.00
224,402.00
Average Dilution Earnings
3,175.00
11,582.00
11,648.00
4,736.00
4,717.00
Diluted NI Available to Com Stockholders
67,766.00
191,304.00
225,569.00
270,590.00
229,119.00
Basic EPS
1.01
2.75
3.07
3.24
2.21
Diluted EPS
0.80
2.20
2.37
2.87
2.02
Basic Average Shares
62,992.25
65,435.00
69,644.00
82,062.00
101,320.00
Diluted Average Shares
68,513.00
86,876.00
95,249.00
94,311.00
113,554.00
Total Operating Income as Reported
--
--
-36,946.00
375,103.00
321,123.00
Total Expenses
191,492.00
196,578.00
124,344.00
16,763.00
15,671.00
Net Income from Continuing & Discontinued Operation
64,591.00
179,722.00
213,921.00
265,854.00
224,402.00
Normalized Income
103,759.92
169,417.28
18,569.92
260,355.52
223,766.67
Interest Income
18,159.00
15,818.00
6,369.00
1,839.00
1,524.00
Interest Expense
23,412.00
19,157.00
15,789.00
19,070.00
18,331.00
Net Interest Income
-5,253.00
-3,339.00
-9,420.00
-17,231.00
-16,807.00
EBIT
97,307.00
213,255.00
302,738.00
464,346.00
372,576.00
EBITDA
123,208.00
235,039.00
308,319.00
464,346.00
372,576.00
Reconciled Cost of Revenue
42,563.00
42,640.00
13,793.00
--
--
Reconciled Depreciation
25,901.00
21,784.00
5,581.00
--
--
Net Income from Continuing Operation Net Minority Interest
64,591.00
179,722.00
213,921.00
265,854.00
224,402.00
Total Unusual Items Excluding Goodwill
-44,811.00
11,129.00
254,496.00
6,638.00
766.00
Total Unusual Items
-44,811.00
11,129.00
254,496.00
6,638.00
766.00
Normalized EBITDA
168,019.00
223,910.00
53,823.00
457,708.00
371,810.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-5,642.08
824.28
59,144.92
1,139.52
130.67
12/31/2020 - 10/5/2004
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
ARMP Armata Pharmaceuticals, Inc.
2.2500
+7.14%
XNCR Xencor, Inc.
25.01
+3.78%
ELVN Enliven Therapeutics, Inc.
24.54
-3.42%
TBPH Theravance Biopharma, Inc.
9.47
-1.46%
NUVB Nuvation Bio Inc.
2.8000
+3.70%
CGON CG Oncology, Inc.
33.47
+3.49%
PBYI Puma Biotechnology, Inc.
3.0000
+3.45%
LGND Ligand Pharmaceuticals Incorporated
119.19
+2.27%
ACLX Arcellx, Inc.
90.44
+3.69%
KYMR Kymera Therapeutics, Inc.
44.98
+3.38%